GleamWall
中文EN

AYTU AYTU BIOPHARMA, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1385818 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.1%
TTM net income YoY-53.8%
TTM EPS YoY-55.0%
Revenue 3-yr CAGR-15.7%
Net income 3-yr CAGR—

Margins

Gross margin63.3%
Operating margin-18.4%
Net margin-34.3%
FCF margin—
EBITDA margin-14.2%

Returns

ROE-73.4%
ROA-17.9%
ROIC (approx.)-87.4%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.33x
Current ratio1.07x
Interest coverage-6.01x

Cash quality & payout

Operating cash flow / net income-0.18x
Accruals ratio-21.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$57.57M$66.38M
Cost of revenue$20.75M$20.55M
Gross profit$36.82M$45.83M
R&D expense$0$1.33M
SG&A expense$19.27M$17.38M
Operating income-$8.31M-$7.83M
Interest expense$1.90M$3.70M
Pretax income-$14.23M-$13.74M
Income tax$21,000$437,000
Net income-$14.25M-$13.56M
EBITDA-$4.38M-$2.45M
EPS (basic)-1.16-2.16
EPS (diluted)——
Balance sheet
Cash & equivalents$26.31M$30.95M
Receivables$22.78M$31.16M
Inventory$6.86M$11.43M
Current assets$61.76M$79.18M
PP&E, net$385,000$532,000
Intangibles$41.40M$42.20M
Total assets$105.01M$124.18M
Current liabilities$54.66M$63.06M
Short-term debt$1.86M$1.86M
Long-term debt$9.10M$10.89M
Total debt$10.96M$12.75M
Total liabilities$69.73M$105.21M
Shareholders' equity$35.27M$18.97M
Net debt-$15.35M-$18.20M
Shares outstanding10.73M8.98M
Cash flow statement
Operating cash flow$3.28M-$1.94M
Capital expenditure$29,000$228,000
Free cash flow$3.25M-$2.17M
Investing cash flow-$29,000-$2.56M
Financing cash flow-$7.90M$15.44M
Depreciation & amortization$3.93M$5.38M
Stock-based compensation$691,000$576,000

Free plan shows the latest 2 periods; Pro shows all 21 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.